Dr. Sean Cao is currently the Managing Director of C-Bridge Capital, a health care Private Equity fund based in China, and the President and interim CEO of Everest Medicines, a biopharma company focused on developing innovative therapeutics in China. Prior to that, Dr. Cao was VP of Global Business Development at Simcere Pharmaceutical Group, responsible for the global BD strategy for Simcere, including licensing, acquisition, partnering and investment activities. Dr. Cao was also the President and Board Director at Simcere of America, a wholly owned subsidiary of Simcere.
Prior to that, Dr. Cao was the Senior Director of Alternative Partnership, Evaluation & Expertise at Sanofi, where he led the externalization effort in Global R&D. In addition, Dr. Cao was also responsible for managing the evaluation of acquisition/in-licensing opportunities, directly responsible for the due diligence of multiple investment decisions worth more than $4B. Before Sanofi, Sean was an associate at New Leaf Venture Partners, a leading healthcare VC firm based in New York. Sean worked in the pharmaceutical and diagnostic industries for over eight years before joining New Leaf, first at Aventis, then at Johnson & Johnson. Sean is a member of BayHelix, a premier organization of Chinese life sciences business leaders.
Sean holds a Ph.D. in Microbiology from the University of Virginia, an MBA with honor from the Wharton School of the University of Pennsylvania, and a B.Sc. in Microbiology from Nankai University.